Zhen Su, Marengo Therapeutics CEO

Ipsen jumps in­to the TCR space, team­ing with start­up helmed by for­mer Mer­ck KGaA can­cer chief

Ipsen is con­tin­u­ing its deal­mak­ing ways to kick off the new month, shelling out a hand­some $45 mil­lion up­front to a TCR up­start Mon­day morn­ing.

The French phar­ma com­pa­ny is part­ner­ing with Maren­go Ther­a­peu­tics on two ex­per­i­men­tal drugs, with the biotech tak­ing on pre­clin­i­cal work and Ipsen plan­ning to run the clin­i­cal stud­ies. And the pay­off for Maren­go could be huge — Ipsen is promis­ing near­ly $1.6 bil­lion in mile­stones if both pro­grams hit all of their goals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.